«Experts tout immediate quadruple therapy for HFrEF patients»

Authors: Golukhova E.Z.

Company: Bakoulev National Medical Research Center for Cardiovascular Surgery, Moscow, 121552, Russian Federation

For correspondence:  Sign in or register.

Type:  Editorial article


DOI: https://doi.org/10.24022/1997-3187-2020-14-3-201-205

For citation: Golukhova E.Z. «Experts tout immediate quadruple therapy for HFrEF patients». Creative Cardiology. 2020; 14 (3): 201–5 (in Russ.). DOI: 10.24022/ 1997-3187-2020-14-3-201-205

Received / Accepted:  20.10.2020 / 21.10.2020

Keywords: cchronic heart failure heart failure treatment cardiac resynchronization therapy

Download
Full text:  

 

Abstract

The article presents a modern analysis of chronic heart failure therapy including medical treatment and cardiac resynchronization therapy in patients with severe left ventricular dysfunction according to latest trials and longterm follow-up results.

References

  1. Zoler M.L. Experts tout immediate quadruple therapy for HFrEF patients. Medscape. 2020. https://www.medscape.com/viewarticle/939465 (дата обращения 11.11.2020)
  2. Greene S.J., Butler J., Albert N.M., DeVore A.D., Sharma P.P., Duffy C.I. Medical therapy in chronic heart failure with reduced ejection fraction: The CHAMP-HF Registry. JACC. 2018; 72 (4): 351–66. DOI: 10.1016/j.jacc.2018.04.070
  3. Vaduganathan M., Claggett B.L., Jhund P.S., Cunningham J.W., Ferreira J.P., Zannad F. et al. Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with reduced ejection fraction: a comparative analysis of three randomized controlled trials. Lancet. 2020; 396 (10244): 121–8. DOI: 10.1016/S0140-6736(20)30748-0
  4. Zannad F., McMurray J.J.V., Krum H., van Veldhuisen D.J., Swedberg K., Shi H. et al. Eplerenone in patients with systolic heart failure and mild symptoms. N. Engl. J. Med. 2011; 364 (1): 11–21. DOI: 10.1056/NEJMoa1009492
  5. McMurray J.J.V., Packer M., Desai A.S., Gong J., Lefkowitz M.P., Rizkala A.R. et al. Angiotensin-Neprilysin inhibition versus Enalapril in heart failure. N. Engl. J. Med. 2014; 371 (11): 993–1004. DOI: 10.1056/NEJMoa1409077
  6. McMurray J.J.V., Solomon S.D., Inzucchi S.E., Kober L., Kosiborod M.N., Martinez F.A. et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N. Engl. J. Med. 2019; 381 (21): 1995–2008. DOI: 10.1056/NEJMoa1911303
  7. Rickard J., Patel D, Park C., Marine J.E., Sinha S., Tang W. et al. Long-term outcomes in patients with a left ejection fraction 15% undergoing cardiac resynchronization therapy. Published online 28.10.2020. J. Am. Coll. Cardiol. Clin. Electrophysiol. DOI: 10.1016/j.jacep.2020.07.025

About Authors

Elena Z. Golukhova, Dr. Med. Sc., Professor, Academician of Russian Academy of Sciences, Сhief of Chair, Acting Head of Bakоulev National Medical Research Center for Cardiovascular Surgery, ORCID

Chief Editor

Leo A. Bockeria, MD, PhD, DSc, Professor, Academician of Russian Academy of Sciences, President of Bakoulev National Medical Research Center for Cardiovascular Surgery